news

31/5/2024
pharma& Updates on the Phase 3 ATHENA-COMBO Trial Evaluating rucaparib (Rubraca®) in Combination with nivolumab in First-line Maintenance Treatment in Women with Advanced Ovarian Cancer

30/4/2024
pharma& joins the United Nations Global Compact

16/3/2024
pharma&’s Rubraca® (rucaparib) ATHENA-MONO Clinical Trial Data in First-Line Maintenance Treatment Suggest Benefit Continues Beyond Completion of Treatment and First Progression

1/2/2024
pharmaand GmbH’s Rubraca®▼ (rucaparib) approved in the United Kingdom as a First-Line Maintenance Treatment in Advanced Ovarian Cancer

1/2/2024
pharmaand GmbH and GHN Pharma Nordic AB Announce Collaboration Extension and Expansion
17/1/2024
pharma& Acquires the Global Rights to satraplatin from Dayton Therapeutics
20/11/2023
European Commission Approves pharmaand GmbH’s Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
16/10/2023
pharmaand GmbH Receives Positive CHMP Opinion for Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer

read more in our news archive